Puma Biotechnology Q4 2025 slides: NERLYNX revenue rises 15% sequentially

Net NERLYNX revenue was $59.9M in Q4'25, up 15% sequential and 10% YoY, contributing to total company revenue of $75.5M (including $15.6M royalties). Puma sold 3,298 ex-factory bottles in Q4'25 (+11% YoY, +12% QoQ) and built inventory ($5.7M / 343 bottles), signaling channel stocking. Management flagged declining new prescriptions and patient enrollments despite a third consecutive year of profitability; the stock fell ~3.03% on the update. Guidance: Q2'26 revenue $52.0M and Q3'26 revenue $60.5M with EPS estimates of $0.07 and $0.22, respectively.

Analysis

Puma’s dynamics look less like a pure growth story and more like a volume- and cadence-driven arbitrage between durable patient persistence and per-patient revenue compression. The shift toward lower initiation dosing materially changes the unit economics: better adherence lifts lifetime patient counts but reduces average revenue per treated patient, so topline upside will be tethered to sustained new-starts growth, not just retention.

The inventory build-up and a step-change in international royalty timing create asymmetric quarter-to-quarter variance — partners can deliver lumpier dollars that buoy near-term results but raise downside when channel stocking normalizes. That makes headline beats fragile: misses are more likely if prescriptions slide further or if partner launch schedules slip, and the market will punish guidance revisions quickly.

Distribution partners (specialty pharmacies and large wholesalers) are secondary beneficiaries: they collect margin and cross-sell services as oral-oncology throughput grows, creating a steady, lower-volatility cash flow stream versus Puma’s lumpy royalties. The most actionable catalysts are non-financial — favorable guideline inclusions, label expansions, or positive combo trial readouts — which would reverse prescriber hesitancy and re-accelerate new-starts over 3–12 months.

Key tail risks include accelerated competitive displacement in the extended-adjuvant niche or sudden payer formulary pressure tied to tolerability concerns, either of which could compress pricing or depress new-starts rapidly. Monitor partner launch cadence and specialty pharmacy fill rates as higher-fidelity leading indicators of sustainable demand rather than headline quarterly revenue alone.

Key Decisions for Investors

• PBYI - Core long (equity): Initiate a 1.5% portfolio position in PBYI, scale in over 3–6 weeks on any >8% intraday pullback. Time horizon 12 months; target 40–60% upside if international royalty cadence continues and new-starts stabilize. Hard stop at -25% from average entry to limit exposure to a guidance-driven re-rate.
• PBYI - Options asymmetric: Buy a Jan 2027 bull-call spread (e.g., modestly OTM strikes) sized to equal ~1.5% portfolio notional to capture upside from guideline/label catalysts while capping premium outlay. Rationale: limited downside cost but levered exposure to multi-quarter recovery; close on any >80% intrinsic gain or if partner royalty outlook weakens.
• MCK / CVS - Defensive infra longs: Allocate 2% portfolio split between McKesson (MCK) and CVS (CVS) equities with 6–12 month horizon to capture stable specialty pharmacy and distributor cashflows tied to oral-oncology volume. Target combined 15–25% upside; stop-loss 12% — these stocks act as soft hedges to Puma’s headline volatility.
• PBYI - Hedge (options): Buy a 3–6 month put spread on PBYI sized to hedge 50% of the equity leg (trade 1) to protect against inventory-normalization or a surprise drop in new prescriptions around upcoming quarterly guidance. Cost is the premium; payoff protects against a guidance-driven drawdown in the near term.